It’s been almost 10 years since CureDuchenne funded a little know biotech company, Prosensa, in the Netherlands. With only $10,000 in our bank account, we committed to fund a $1.3 Million project […]
GSK will be announcing results from their Phase llb study this week. We will keep you updated on the news as it comes in. Here is the note from GSK: […]
Data to Be Presented at the Muscular Dystrophy Association Scientific Conference CAMBRIDGE, MA–(Marketwired – April 05, 2013) – Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today […]
• First patient clinical trials of SMT C1100 expected to start H2 2013 •Summit to showcase programme at international scientific conference Oxford, UK, 21 March 2013 – Summit (AIM: SUMM), […]
Dear Debra, Since my last email you may have seen a recent story that appeared on an investment tips website regarding a presentation on drisapersen made at the Duchenne Parent […]
CureDuchenne was honored to host a webinar today, in collaboration with PPMD and MDA to discuss accelerated approval for drugs for rare diseases. Dr. Robert Temple, director of the […]
Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan […]
GSK has sent out this update on their Duchenne trial. The last patient has been recruited within the drisapersen US Phase II clinical study [www.clinicaltrials.gov NCT01462292]. This exploratory study aims […]
Exon duplication mutations have been an area of great interest to CureDuchenne, and last year, CureDuchenne funded research specifically directed toward these mutations in Duchenne. Dr. Kevin Flanigan at Nationwide […]
